RNA, once considered “undruggable,” is now recognized as a dynamic and versatile therapeutic target, with vast potential in treating diseases ranging from viral and bacterial infections to cancer and genetic disorders.
At CrystalsFirst, we are thrilled to be part of this transformation as a partner of TargetRNA – EU Horizon funded Marie Skłodowska-Curie Action (MSCA) doctoral training network funded by the EU Horizon program.
The kick off at the University of Bergen brought together top academic institutions and innovative biotech companies from across Europe. Led by Professor Ruth Brenk, TargetRNA aims to train the next generation of scientists in the rational design of small molecules that specifically target RNA.
From structural biology and cheminformatics to live-cell screening and fragment-based drug discovery, this project brings cutting-edge science and interdisciplinary collaboration to the heart of RNA-targeted therapeutics.
At CrystalsFirst, we’re contributing our expertise in structural biology, structure-based drug discovery and machine learning to tackle the unique challenges of RNA targeting. We’re excited to support the training talented PhD candidates and to explore new RNA-binding chemotypes with true therapeutic potential.
Subscribe to stay tuned